However, the analysis of circulating biomarkers, namely Soluble fms-like tyrosine kinase- (sFlt-1) and placental growth factor (PlGF), the two that have most often been studied in detail), and of utero-placental flows, where available (Doppler study is economically less demanding, and can be performed rapidly at the bedside) can support the differential diagnosis between CKD and PE and help guide post-pregnancy follow-up (Figure 4) [123,124,125,126,127]. This evidence concerns the gene PGF and chronic kidney disease.